{"id":"W4416140966","doi":"10.1093/neuonc/noaf201.0506","title":"CTNI-09. VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Children's Hospital Research Institute of Manitoba","funders":"","keywords":"Randomized controlled trial; Clinical endpoint; Radiation therapy; Placebo; Chemoradiotherapy; Clinical trial; Quality of life (healthcare); Intention-to-treat analysis; Maintenance therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0110398,0.003284349,0.004437041,0.0009959385,0.002005719,0.001937972,0.003574527,0.004122381,0.03375927],"category_scores_gemma":[0.006352855,0.001809468,0.002168508,0.001371408,0.002329769,0.001779372,0.0008503741,0.0059658,0.008225417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002637455,"about_ca_system_score_gemma":0.01186429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001931889,"about_ca_topic_score_gemma":0.006030297,"domain_scores_codex":[0.9961052,0.002212694,0.0003187831,0.0005015708,0.0003609479,0.0005007873],"domain_scores_gemma":[0.9969471,0.0004063641,0.0006864578,0.0003926442,0.0004151142,0.001152332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9415771,0.01425536,0.0006280002,0.004097176,0.0004257619,0.000136748,0.0001484782,0.0008053185,0.005750488,0.001378632,0.01426529,0.01653158],"study_design_scores_gemma":[0.9504862,0.03346637,0.0008317393,0.0003292327,0.0002453294,0.00006393212,0.00003116332,0.0004657628,0.0008724155,0.0005361963,0.01263734,0.00003424622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.03753814,0.001687688,0.003322912,0.001001414,0.0008968354,0.942346,0.008283879,0.0003483616,0.00457475],"genre_scores_gemma":[0.04064339,0.001339244,0.006962412,0.001528775,0.000292094,0.9419426,0.003258754,0.00005011968,0.003982639],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.03375927,"threshold_uncertainty_score":0.112936,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03381051816741617,"score_gpt":0.3980270223201019,"score_spread":0.3642165041526857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}